blog

At Umoja, we know that a cancer immunotherapy is only as good as the patients it reaches. We can do the best, most innovative, most exciting science at the bench, but if the manufacturing process is not scalable, the effort will be too large to ultimately meet the needs of all patients who might benefit. […]

Looking back over the past year, it is gratifying as CEO to reflect on the extraordinary progress we’ve made at Umoja Biopharma.   This year has had no shortage of major accomplishments for the company. Topping the list is our recent closing of an oversubscribed $210 million Series B funding round. We view our success